Skip to main content

Table 1 Preoperative baseline data of study group and control group

From: Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

  Group A
ASA alone
%(n = 106)
Group B
Ticagrelor +ASA
%(n = 55)
p-Value
Age (years) 64 ± 8 61 ± 10 0.034
Sex, Male (n,%) 87 (92) 96 (53) 0.092
Risk profile
 Diabetes Mellitus 42 (45) 47 (26) 0.622
 Hypertension 71 (75) 76 (42) 0.461
 Hyperlipidemia 75 (80) 76 (42) 0.850
 Smoking, current 38 (40) 54 (30) 0.002
 Smoking, past 12 (13) 5 (3) 0.267
 Obesity 16 (17) 25 (15) 0.207
Previous CAD 36 (38) 40 (22) 0.733
 Coronary stents in situ 26 (28) 51 (25) 0.003
 Paroxysmal atrial fibrillation 7 (7) 2 (1) 0.054
 Renal Failure 3 (3) 5 (3) 0.414
 Congestive heart failure 18 (19) 13 (7) 0.500
 Peripheral vascular disease 7 (7) 2 (1) 0.265
 Cerebrovascular accident 6 (6) 9 (5) 0.514
 COPD 6 (6) 5 (2) 0.716
Medications
 Aspirin 92 (97) 98(54) 0.137
 Anticoagulant therapy (VKA/DOACs) 8 (9) 2 (1) 0.254
 ACEi/ARB 48 (51) 61 (38) 0.002
 β Blockers 72 (76) 85 (47) 0.085
 Calcium Channel Blockers 26 (28) 27 (15) 0.854
  1. CAD Coronary artery disease, ASA acetylsalicylic acid, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme, VKA Vitamin K antagonists, DOACs Direct oral anticoagulants